Evidence map›Paper›PMID 32913975›Full record

ArticleJCO precision oncology2017

Participant Attitudes Toward an Intensive Trial of Multiple Biopsies, Multidimensional Molecular Analysis, and Reporting of Results in Metastatic Triple-Negative Breast Cancer.

Nicole M Kuderer, Kimberly A Burton, Sibel Blau, Francis Senecal, Vijayakrishna K Gadi, Stephanie Parker, Elisabeth Mahen, David Veenstra, Josh J Carlson, Gary H Lyman and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Nicole M Kuderer: University of Washington; and , Fred Hutchinson Cancer Research Center, Seattle; and , , and , Northwest Medical Specialties, Puyallup and Tacoma, WA.
Kimberly A Burton: University of Washington; and , Fred Hutchinson Cancer Research Center, Seattle; and , , and , Northwest Medical Specialties, Puyallup and Tacoma, WA.
Sibel Blau: University of Washington; and , Fred Hutchinson Cancer Research Center, Seattle; and , , and , Northwest Medical Specialties, Puyallup and Tacoma, WA.
Francis Senecal: University of Washington; and , Fred Hutchinson Cancer Research Center, Seattle; and , , and , Northwest Medical Specialties, Puyallup and Tacoma, WA.
Vijayakrishna K Gadi: University of Washington; and , Fred Hutchinson Cancer Research Center, Seattle; and , , and , Northwest Medical Specialties, Puyallup and Tacoma, WA.
Stephanie Parker: University of Washington; and , Fred Hutchinson Cancer Research Center, Seattle; and , , and , Northwest Medical Specialties, Puyallup and Tacoma, WA.
Elisabeth Mahen: University of Washington; and , Fred Hutchinson Cancer Research Center, Seattle; and , , and , Northwest Medical Specialties, Puyallup and Tacoma, WA.
David Veenstra: University of Washington; and , Fred Hutchinson Cancer Research Center, Seattle; and , , and , Northwest Medical Specialties, Puyallup and Tacoma, WA.
Josh J Carlson: University of Washington; and , Fred Hutchinson Cancer Research Center, Seattle; and , , and , Northwest Medical Specialties, Puyallup and Tacoma, WA.
Gary H Lyman: University of Washington; and , Fred Hutchinson Cancer Research Center, Seattle; and , , and , Northwest Medical Specialties, Puyallup and Tacoma, WA.
C Anthony Blau: University of Washington; and , Fred Hutchinson Cancer Research Center, Seattle; and , , and , Northwest Medical Specialties, Puyallup and Tacoma, WA.
Northwest Medical Specialties · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMultidimensional molecular analysis of tumor tissue intensively over space and time can provide insight into how cancers evolve and escape treatment. Attitudes of participants in such trials have not been assessed. We explored patient views regarding an intensive study incorporating multiple biopsies, multidimensional molecular testing, and drug response predictions that are reported to the oncologist and patient. PATIENTS AND

methodsA structured, self-administered survey was conducted among the first 15 patients enrolled in ITOMIC-001 (Intensive Trial of Omics in Cancer). Patients with metastatic triple-negative breast cancer were accrued at two sites in Washington state. Surveys containing 17 items were administered at enrollment and after the return of results. Surveys explored perceptions regarding risks, personal benefits, benefits to others, uncertainties associated with interpreting complex molecular results, concerns regarding multiple biopsies, and potential loss of confidentiality. At follow-up, three additional unique items explored patient coping.

resultsAll participants expressed a strong desire for their experiences to benefit others, and all perceived a higher likelihood of deriving benefit than described during detailed consent discussions. Loss of confidentiality ranked lowest among patient concerns. Despite acknowledging uncertainties and risks inherent in complex molecular testing for clinical reporting, participants wanted access to findings in evaluating treatment choices, even if the best available evidence was weak. Follow-up surveys demonstrated relatively little change in attitudes, although concern about study biopsies generally declined. Study participation helped several patients cope better with their disease.

conclusionIn advanced breast cancer, these findings demonstrate the feasibility of engaging motivated patients in trials that navigate the uncertainties associated with intensive spatial and longitudinal multidimensional molecular testing for the purpose of advancing precision medicine.

Identifiers

PMID32913975
PMCPMC7446457
OpenAlexW2747061783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.